natgillin/translations-raw huggingface dataset:
In studies to explore extending the dosing interval (40,000 IU once weekly and 80,000, 100,000, and 120,000 IU biweekly), a linear but non-dose-proportional relationship was observed between mean Cmax and dose, and between mean AUC and dose at steady state. 
V študijah, v katerih so raziskali podaljšan interval odmerjanja (40.000 i.e. enkrat na teden ter 80.000, 100.000 in 120.000 i.e. na vsaka dva tedna), so opazili linearno razmerje, ki ni bilo sorazmerno z odmerkom, med povprečnim Cmax in odmerkom ter med povprečnim AUC in odmerkom v stanju dinamičnega ravnovesja.
Significantly fewer patients received RBC transfusions in the epoetin alfa plus SOC arm (5.8% versus 11.4%); however, significantly more patients had thrombotic vascular events in the epoetin alfa plus SOC arm (2.8% versus 1.4%). 
Značilno manj bolnikov je prejelo transfuzije RKC v kraku z epoetinom alfa in standardno nego (5,8 % v primerjavi z 11,4 %); vendar pa je imelo značilno več bolnikov trombotične žilne dogodke v kraku z epoetinom alfa in standardno nego (2,8 % v primerjavi z 1,4 %).
The effect of epoetin alfa (300 IU/kg or 100 IU/kg) on the exposure to allogeneic blood transfusion has been evaluated in a placebo-controlled, double-blind clinical trial in non-iron deficient adult patients scheduled for major elective orthopaedic hip or knee surgery. 
Učinek epoetina alfa (300 i.e./kg ali 100 i.e./kg) na izpostavljenost alogenski transfuziji krvi so ocenili v s placebom nadzorovanem, dvojno slepem kliničnem preskušanju pri odraslih bolnikih brez pomanjkanja železa, ki imajo načrtovan večji elektivni ortopedski kirurški poseg na kolku ali kolenu.
Additional studies compared the 40,000 IU once-weekly regimen of epoetin alfa with biweekly doses ranging from 80,000 to 120,000 IU subcutaneously. 
V dodatnih študijah so primerjali režim epoetina alfa 40.000 i.e. enkrat na teden z odmerki enkrat na dva tedna od 80.000 do 120.000 i.e., subkutano.
Use the syringe within 3 days of taking it out of the refrigerator. 
Ko injekcijsko brizgo vzamete iz hladilnika, jo porabite v roku 3 dni.
While on Epoetin alfa HEXAL, some people need medicines to reduce the risk of blood clots. 
Med uporabo zdravila Epoetin alfa HEXAL morajo nekatere osebe jemati zdravila za zmanjšanje tveganja za nastanek krvnih strdkov.
Treatment should only be given to patients with moderate anaemia (haemoglobin [Hb] concentration range between 10 to 13 g/dL [6.2 to 8.1 mmol/L], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). 
Zdravilo Epoetin alfa HEXAL smemo uporabiti samo pri bolnikih z zmerno anemijo (razpon koncentracije hemoglobina [Hb] od 10 do 13 g/dl [6,2 do 8,1 mmol/l] brez pomanjkanja železa), če postopki za ohranjanje krvi niso na voljo ali ne zadostujejo, kadar je za večji elektivni kirurški poseg potrebna velika količina krvi (4 ali več enot krvi za ženske ali 5 ali več enot za moške).
• If there is a medical need to reduce the time before your operation, you will be given a daily dose of 300 IU/kg for up to ten days before surgery, on the day of surgery and for four days immediately afterwards. 
• Če obstaja medicinska potreba za zmanjšanje časa pred kirurškim posegom, boste prejemali dnevni odmerek 300 i.e./kg do deset dni pred kirurškim posegom, na dan posega in še štiri dni po posegu.
Epoetin alfa has been shown to stimulate red blood cell production in order to augment autologous blood collection, and to limit the decline in haemoglobin in adult patients scheduled for major elective surgery who are not expected to predeposit their complete perioperative blood needs. 
Pokazalo se je, da epoetin alfa spodbuja nastajanje rdečih krvnih celic z namenom povečanja odvzema avtologne krvi in zmanjšanja upada hemoglobina pri odraslih bolnikih, naročenih na večji elektivni kirurški poseg, pri katerih se ne pričakuje, da bodo zbrali kri za vse njihove potrebe pri operaciji.
There are no or limited amount of data from the use of epoetin alfa in pregnant women. 
Podatkov o uporabi epoetina alfa pri nosečnicah ni oziroma so omejeni.
At the time of clinical data cutoff, the median progression free survival (PFS) per investigator assessment of disease progression was 7.4 months in each arm (HR 1.09, 95% CI: 0.99, 1.20), indicating the study objective was not met. 
V času kliničnega preseka je bilo mediano preživetje brez napredovanja (PFS - progression free survival) po raziskovalčevi oceni napredovanja bolezni 7,4 mesece v vsakem kraku (razmerje ogroženosti 1,09; 95 % IZ: 0,99; 1,20), kar kaže, da cilj študije ni bil dosežen.
In most anaemic subjects with cancer receiving cyclic chemotherapy, CL/F was lower after subcutaneous doses of 40,000 IU once weekly and 150 IU/kg, 3 times-per-week compared with the values for healthy subjects. 
Pri večini anemičnih oseb z rakom, ki so prejemale ciklično kemoterapijo, je bil CL/F po subkutanih odmerkih 40.000 i.e enkrat na teden in 150 i.e./kg 3-krat na teden nižji v primerjavi z vrednostmi za zdrave osebe.
You may still be able to use Epoetin alfa HEXAL, but discuss it with your doctor first: 
Morda boste lahko še vedno uporabljali zdravilo Epoetin alfa HEXAL, vendar se najprej posvetujte s svojim zdravnikom:
The safety and efficacy of epoetin alfa in paediatrics have not been established. 
Varnost in učinkovitost epoetina alfa pri pediatričnih bolnikih nista bili dokazani.
Available evidence suggests patients with haematological malignancies and solid tumours respond equivalently to epoetin alfa therapy, and that patients with or without tumour infiltration of the bone marrow respond equivalently to epoetin alfa therapy. 
Razpoložljivi dokazi kažejo, da se bolniki s hematološkimi malignostmi in solidnimi tumorji na zdravljenje z epoetinom alfa odzivajo ekvivalentno in da se bolniki z infiltracijo tumorja v kostni mozeg in brez nje na zdravljenje z epoetinom alfa odzivajo ekvivalentno.
The needle safety guard covers the needle after injection to prevent needle stick injury. 
Uporaba napolnjene injekcijske brizge z varnostno zaščito za iglo Varnostna zaščita za iglo po injiciranju iglo prekrije, da bi tako preprečila poškodbe zaradi vboda z iglo.
Use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 g/dL or 6.2 to 8.1 mmol/L) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1,800 mL). 
Uporabo je treba omejiti na bolnike z zmerno anemijo (npr. razpon koncentracije hemoglobina od 10 do 13 g/dl ali od 6,2 do 8,1 mmol/l), ki jim program avtolognega darovanja krvi ni na voljo in pri katerih se pričakuje zmerna izguba krvi (od
After injecting the liquid, remove the needle and let go of your skin. 
Ko ste raztopino vbrizgali, iglo izvlecite in kožo izpustite.
The most frequently occurring adverse drug reactions observed in clinical trials of epoetin alfa are diarrhoea, nausea, vomiting, pyrexia and headache. 
Najpogostejši neželeni učinki zdravila, ki so se pojavili v kliničnih preskušanjih z epoetinom alfa, so driska, navzea, bruhanje, pireksija in glavobol.
A rise in haemoglobin of greater than 2 g/dL over a four week period should be avoided. 
Izogibati se je treba zviševanju hemoglobina za več kot 2 g/dl v obdobju štirih tednov.
• Arm or leg pain. 
• Bolečina v roki ali nogi.
• Do not attempt to inject yourself unless you have been trained to do so by your doctor or nurse. 
• Zdravila si ne poskušajte injicirati sami, če vas tega ni naučil zdravnik ali medicinska sestra.
The safety of epoetin alfa has not been established in patients with hepatic dysfunction. 
Varnost epoetina alfa ni bila dokazana pri bolnikih z jetrno disfunkcijo.
In the 20-week study (n = 225), no significant difference was observed in the primary efficacy endpoint, i.e. the proportion of patients who required a RBC transfusion after Day 28 (62% of epoetin alfa patients versus 69% of standard therapy patients). 
V 20-tedenski študiji (n = 225) niso opazili značilnih razlik v primarnem opazovanem dogodku učinkovitosti, tj. v deležu bolnikov, pri katerih je bila potrebna transfuzija RKC po 28. dnevu (62 %
It is recommended that the platelet count is regularly monitored during the first 8 weeks of therapy. 
V prvih osmih tednih zdravljenja se priporoča redno spremljanje števila trombocitov.
A randomised, double-blind, placebo-controlled, multicentre study evaluated the efficacy and safety of epoetin alfa in adult anaemic subjects with low- or intermediate-1-risk MDS. 
V randomizirani, dvojno slepi, s placebom nadzorovani multicentrični študiji so ocenjevali učinkovitost in varnost epoetina alfa pri odraslih osebah z anemijo in MDS z nizkim ali srednjim-1
Epoetin alfa HEXAL is indicated for the treatment of symptomatic anaemia (haemoglobin concentration of ≤ 10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (< 200 mU/mL). 
Zdravilo Epoetin alfa HEXAL je indicirano za zdravljenje simptomatske anemije (koncentracija hemoglobina ≤ 10 g/dl) pri odraslih s primarnimi mielodisplastičnimi sindromi (MDS) z nizkim ali srednjim-1 tveganjem, ki imajo nizke vrednosti eritropoetina v serumu (< 200 me./ml).
300 IU/kg 
300 i.e./kg
Epoetin alfa HEXAL is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. 
Zdravilo Epoetin alfa HEXAL je indicirano za zdravljenje odraslih, pri katerih s kemoterapijo zdravimo solidne tumorje, maligni limfom ali multipli mielom, in pri tveganju za transfuzijo, ki ga ocenimo glede na bolnikovo splošno zdravstveno stanje (npr. kardiovaskularni status, prisotnost anemije že na začetku zdravljenja s kemoterapijo) za zdravljenje anemije in zmanjšanje potrebe po transfuziji.
Epoetin alfa HEXAL can reduce the need for a blood transfusion. 
Zdravilo Epoetin alfa HEXAL lahko zmanjša potrebo po transfuziji krvi.
Patients scheduled for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis, as thrombotic and vascular events may occur in surgical patients, especially in those with underlying cardiovascular disease. 
Bolniki, naročeni na večji elektivni ortopedski poseg, morajo prejeti ustrezno antiagregacijsko profilakso zaradi tveganja za trombotične in žilne dogodke pri kirurških bolnikih, še posebej pri tistih z boleznijo srca in ožilja.
In chronic renal failure patients, the half-life of intravenously administered epoetin alfa is slightly prolonged, approximately 5 hours, compared to healthy subjects. 
Pri bolnikih s kronično z ledvično odpovedjo je razpolovni čas intravensko danega epoetina alfa v primerjavi z zdravimi osebami nekoliko podaljšan, približno 5 ur.
Urticaria3 
Pogostnost urtikarija3
Adults on chemotherapy 
Odrasli bolniki na kemoterapiji
In case of larger volumes, more than one site should be chosen for the injection. 
V primeru večjih količin je treba zdravilo injicirati na več mestih.
Epoetin alfa was administered at 75 IU/kg/week intravenously in 2 or 3 divided doses post-dialysis, titrated by 75 IU/kg/week at intervals of 4 weeks (up to a maximum of 300 IU/kg/week), to achieve a 1 g/dL/month increase in haemoglobin. 
Epoetin alfa so dajali v odmerku 75 i.e./kg/teden intravensko, v 2 ali 3 razdeljenih odmerkih po dializi, ki so ga v 4-tedenskih intervalih titrirali po 75 i.e./kg/teden (do največ 300 i.e./kg/teden), za dosego povečanja hemoglobina za 1 g/dl/mesec.
In patients developing sudden lack of efficacy defined by a decrease in haemoglobin (1 to 2 g/dL or 0.62 to 1.25 mmol/L per month) with increased need for transfusions, a reticulocyte count should be obtained and typical causes of non-response (e.g. iron, folate or vitamin B12 deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be investigated. 
Pri bolnikih, pri katerih se je razvilo nenadno zmanjšanje učinka zdravila, ki je opredeljeno kot zmanjšanje koncentracije hemoglobina (za 1 do 2 g/dl ali 0,62 do 1,25 mmol/l na mesec) s povečano potrebo po transfuziji, je treba določiti število retikulocitov in raziskati značilne vzroke neodzivnosti na zdravljenje (npr. pomanjkanje železa, folata ali vitamina B12, zastrupitev z aluminijem, okužba ali vnetje, izguba krvi, hemoliza in fibroza kostnega mozga katerega koli izvora).
The recommended dose is Epoetin alfa HEXAL 600 IU/kg, administered subcutaneously weekly for three weeks (days -21, -14 and -7) prior to surgery and on the day of surgery (day 0). 
Priporočeni odmerek zdravila Epoetin alfa HEXAL je 600 i.e./kg, ki se daje subkutano tedensko v obdobju treh tednov (na 21., 14. in 7. dan) pred kirurškim posegom in na dan kirurškega posega (dan 0).
Your Epoetin alfa HEXAL dose and frequency of administration may be further adjusted to maintain your response to treatment. 
Po potrebi vam lahko odmerek zdravila Epoetin alfa HEXAL in pogostnost uporabe nadalje prilagaja, da se ohrani vaš odziv na zdravljenje.
You may still be able to use Epoetin alfa HEXAL, but discuss it with your doctor first. 
Morda boste kljub temu lahko uporabljali zdravilo Epoetin alfa HEXAL, vendar se najprej posvetujte s svojm zdravnikom.
• If you are on a more extended dosing interval (greater than once weekly) of Epoetin alfa HEXAL, you may not maintain adequate haemoglobin levels and you may require an increase in Epoetin alfa HEXAL dose or frequency of administration. 
• Če uporabljate daljši interval odmerjanja zdravila Epoetin alfa HEXAL (daljši kot enkrat tedensko), morda ne bo mogoče vzdrževati ustrezne ravni hemoglobina in bo treba odmerek ali pogostnost odmerjanja zdravila Epoetin alfa HEXAL povečati.
In order to ensure optimum response to epoetin alfa, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section 4.2): 
Za optimalen odziv na zdravljenje z epoetinom alfa je treba zagotoviti ustrezne zaloge železa in po potrebi dajati nadomestke železa (glejte poglavje 4.2):
After single doses (20,000 to 160,000 IU subcutaneously) of epoetin alfa, a dose-dependent response was observed for the pharmacodynamic markers investigated including: reticulocytes, RBCs, and haemoglobin. 
Zdravi prostovoljci Po enkratnem odmerjanju (20.000 do 160.000 i.e. subkutano) epoetina alfa so opazili od odmerka odvisen odziv preučevanih farmakodinamičnih markerjev, vključno z retikulociti, RKC in hemoglobinom.
Patients with very low initial haemoglobin (< 6 g/dL or < 3.75 mmol/L) may require higher maintenance doses than patients whose initial anaemia is less severe (> 8 g/dL or > 5 mmol/L). 
Bolniki z zelo majhno začetno koncentracijo hemoglobina (< 6 g/dl ali < 3,75 mmol/l) lahko potrebujejo večje vzdrževalne odmerke kot bolniki z blažjo začetno anemijo (> 8 g/dl ali > 5 mmol/l).
The studies either recruited patients who were being treated with chemotherapy (two studies) or used patient populations in which ESAs are not indicated: anaemia in patients with cancer not receiving chemotherapy, and head and neck cancer patients receiving radiotherapy. 
(dve študiji), ali bolniki, pri katerih uporaba ESA ni bila indicirana: anemija pri bolnikih z rakom, ki niso prejemali kemoterapije, in bolniki z rakom glave in vratu, ki so prejemali radioterapijo.
If the patient loses response or haemoglobin concentration drops by ≥ 1 g/dL upon dose reduction the dose should be increased by one dosing step. 
Če se po zmanjšanju odmerka bolnik ne odziva več ali če koncentracija hemoglobina pade za ≥ 1 g/dl, je treba odmerek povečati za en odmerni korak.
Key baseline characteristics for the < 200 mU/mL stratum are shown in the table below. 
Ključne izhodiščne značilnosti skupine < 200 me./ml so prikazane v spodnji preglednici.
The needle safety guard will cover the needle when releasing the plunger. 
Varnostna zaščita za iglo bo po sprostitvi bata pokrila iglo.
Hyperkalaemia has been observed in isolated cases though causality has not been established. 
V posameznih primerih so opazili pojav hiperkaliemije, vendar smrtnih primerov niso ugotovili.
Chronic renal failure 
Kronična ledvična odpoved
Anaphylactic reaction3 
občasni anafilaktična reakcija3
The half-life for the subcutaneous route is estimated to be approximately 24 hours in healthy subjects. 
Razpolovni čas za subkutano uporabo je pri zdravih osebah približno 24 ur.
In female adult patients with metastatic breast cancer, subcutaneous co-administration of 40,000 IU/mL epoetin alfa with trastuzumab 6 mg/kg had no effect on the pharmacokinetics of trastuzumab. 
Pri odraslih bolnicah z metastatskim rakom dojke ni imelo subkutano sočasno dajanje 40.000 i.e./ml epoetina alfa s trastuzumabom 6 mg/kg nobenega učinka na farmakokinetiko trastuzumaba.
Epoetin alfa HEXAL can reduce the need for a blood transfusion in these patients. 
Zdravilo Epoetin alfa HEXAL lahko pri teh bolnikih zmanjša potrebo po transfuziji krvi.
Particular attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal (see section 4.4). 
Treba je biti pozoren na nenaden pojav migreni podobnih glavobolov z zbadanjem, ki so lahko možen opozorilni znak (glejte poglavje 4.4).
If epoetin alfa is given concomitantly with cyclosporin, blood levels of cyclosporin should be monitored and the dose of cyclosporin adjusted as the haematocrit rises. 
Če epoetin alfa dajemo sočasno s ciklosporinom, je treba spremljati koncentracije ciklosporina v krvi in njegov odmerek v primeru zvečanega hematokrita prilagoditi.
Epoetin alfa should be used with caution in patients with epilepsy, history of seizures, or medical conditions associated with a predisposition to seizure activity such as CNS infections and brain metastases. 
Epoetin alfa je treba uporabljati previdno pri bolnikih z epilepsijo, epileptičnimi napadi v anamnezi ali bolezenskimi stanji, povezanimi z nagnjenostjo k epileptični aktivnosti, kot so okužba CŽS in metastaze v možganih.
Following intravenous administration of epoetin alfa in subjects with chronic renal failure, the volume of distribution ranged from 57-107 mL/kg after single dosing (12 IU/kg) to 4264 mL/kg after multiple dosing (48-192 IU/kg), respectively. 
Po intravenskem dajanju epoetina alfa osebam s kronično ledvično odpovedjo je bil razpon volumna porazdelitve od 57-107 ml/kg po enkratnem odmerjanju (12 i.e./kg) oz. do 42-64 ml/kg po večkratnem odmerjanju (48-192 i.e./kg).
In haemodialysed patients, a bolus injection may be given during the dialysis session through a suitable venous port in the dialysis line. 
Bolnikom, ki se zdravijo s hemodializo, lahko zdravilo injiciramo v bolusu prek ustrezne venske odprtine na dializni cevki med postopkom dialize.
In order to ensure optimum response to epoetin alfa, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section 4.4). 
Za optimalen odziv na zdravljenje z epoetinom alfa je treba zagotoviti ustrezne zaloge železa in po potrebi dajati nadomestke železa (glejte poglavje 4.4).
> 13 g/dL (> 8.1 mmol/L), the possibility that epoetin alfa treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded. 
Pri bolnikih z izhodiščno koncentracijo hemoglobina > 13 g/dl (> 8,1 mmol/l) ni mogoče izključiti možnosti, da je zdravljenje z epoetinom alfa lahko povezano z zvečanim tveganjem za pooperativne trombotične žilne dogodke.
Treatment with Epoetin alfa HEXAL has to be initiated under the supervision of physicians experienced in the management of patients with the above indications. 
4.2 Odmerjanje in način uporabe Zdravljenje z zdravilom Epoetin alfa HEXAL je treba začeti pod nadzorom zdravnika, ki ima izkušnje z obravnavo bolnikov z zgoraj navedenimi indikacijami.
If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of Epoetin alfa HEXAL, treatment with Epoetin alfa HEXAL must not be restarted in this patient at any time. 
Če je pri bolniku zaradi uporabe zdravila Epoetin alfa HEXAL prišlo do hude kožne reakcije, kot sta SJS ali TEN, zdravljenja z zdravilom Epoetin alfa HEXAL ni dovoljeno ponovno začeti.
• The starting dose is either 150 IU per kilogram body weight three times a week or 450 IU per kilogram body weight once a week. 
• Začetni odmerek je bodisi 150 i.e. na kilogram telesne mase trikrat na teden ali 450 i.e. na kilogram telesne mase enkrat na teden.
Anaemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a physician's evaluation of the individual patient's clinical course and condition is necessary. 
Simptomi in posledice anemije se lahko razlikujejo glede na starost, spol in sočasne bolezni, zato je potrebna zdravnikova ocena kliničnega poteka bolezni in splošnega stanja posameznega bolnika.
The recommended starting dose is Epoetin alfa HEXAL 450 IU/kg (maximum total dose is 40,000 IU) administered subcutaneously once every week, with not less than 5 days between doses. 
Priporočeni začetni odmerek zdravila Epoetin alfa HEXAL je 450 i.e./kg (največji skupni odmerek je 40.000 i.e.), ki se daje subkutano enkrat na teden, pri čemer med odmerkoma ne sme miniti manj kot
Hypertensive crisis3 
pogosti hipertenzijska kriza3
Early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid, for example, is recommended in these patients. 
Pri teh bolnikih se priporoča zgodnja revizija šanta in trombotična profilaksa, na primer z dajanjem acetilsalicilne kisline.
Where intravenous access is not readily available Epoetin alfa HEXAL may be administered subcutaneously. 
Kjer intravenski dostop ni takoj na razpolago, se zdravilo Epoetin alfa HEXAL lahko daje subkutano.
Adult patients with renal insufficiency not yet undergoing dialysis 
Odrasli bolniki z ledvično insuficienco, ki se še ne zdravijo s hemodializo
The AUCs of the respective pharmacodynamic parameters were similar between the 150 IU/kg, 3 times per week and 40,000 IU, once-weekly dosing regimens in healthy subjects and also in anaemic cancer subjects. 
Vrednosti AUC za zadevne farmakodinamične parametre so bile podobne za režima odmerjanja 150 i.e./kg 3-krat na teden in za 40.000 i.e. enkrat na teden pri zdravih osebah in pri anemičnih osebah z rakom.
• Cough. 
• Kašelj.
This is of uncertain significance in the clinical situation. 
Njihov pomen za klinično prakso ni znan.
• Store in the original package in order to protect from light. 
• Shranjujte v originalni ovojnini za zagotovitev zaščitite pred svetlobo.
Epoetin alfa HEXAL may be given by injection: 
Zdravilo Epoetin alfa HEXAL se lahko daje z injiciranjem:
Epoetin alfa HEXAL is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. 
Zdravilo Epoetin alfa HEXAL je indicirano pred večjimi elektivnimi ortopedskimi kirurškimi posegi pri odraslih brez pomanjkanja železa, pri katerih obstaja veliko tveganje za zaplete pri transfuziji, za zmanjšanje izpostavljenosti alogenim transfuzijam krvi.
The incidence of bone marrow fibrosis was not increased in a study of haemodialysis patients who were treated with epoetin alfa for 3 years compared to a matched control group of dialysis patients who had not been treated with epoetin alfa. 
Študija pri bolnikih na hemodializi, ki so se 3 leta zdravili z epoetinom alfa, ni pokazala večje incidence fibroze kostnega mozga v primerjavi z enako kontrolno skupino bolnikov na dializi, ki se niso zdravili z epoetinom alfa.
1,000 IU/0.5 mL 2,000 IU/1 mL 
1.000 i.e./0,5 ml 2.000 i.e./1 ml
• Epoetin alfa HEXAL is given by injection under the skin. 
• Zdravilo Epoetin alfa HEXAL se daje v obliki injekcije pod kožo.